SUPN - Supernus Pharmaceuticals, Inc.
NEXT EARNINGS:
May 4, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$61.00
DETAILS
HIGH:
$65.00
LOW:
$55.00
MEDIAN:
$63.00
CONSENSUS:
$61.00
UPSIDE:
14.45%
Market Cap:
3.06B
Volume:
2,149,857
Avg Volume:
670,938
52 Week Range:
29.16-57.65
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
0.72
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
674
IPO Date:
2012-05-01
EPS (TTM):
1.34
P/E Ratio:
-0.07
Revenue (TTM):
661.82M
Total Assets:
1.37B
Total Debt:
34.27M
Cash & Equiv:
69.33M
Rev Growth (5Y):
11.0%
EPS Growth (5Y):
-9.1%
FCF Growth (5Y):
4.0%
ROCE:
9.1%
Debt/Equity:
0.03
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $1.01 | $0.82 | +23.2% | $192.1M | $194.7M | -1.3% |
| 2025-08-05 | $0.91 | $0.47 | +93.6% | $165.5M | $168.2M | -1.6% |
| 2025-05-06 | $0.42 | $0.38 | +10.5% | $149.8M | $147.9M | +1.3% |
| 2025-02-25 | $0.75 | $0.46 | +63.0% | $174.2M | $155.3M | +12.2% |
| 2024-11-04 | $1.06 | $0.39 | +171.8% | $175.7M | $154.5M | +13.7% |
| 2024-08-06 | $0.36 | $0.31 | +16.1% | $168.3M | $148.8M | +13.1% |
| 2024-05-08 | $0.26 | $0.38 | -31.6% | $143.6M | $145.8M | -1.5% |
| 2024-02-27 | $0.02 | $0.41 | -95.1% | $164.3M | $155.0M | +6.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 661.82M | 607.52M | 667.24M | 579.77M | 520.40M | 392.75M | 408.90M | 302.24M | 215.00M | 144.43M | 122.05M | 12.02M |
| Net Income | 73.86M | 1.32M | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M | 57.28M | 91.22M | 14.02M | 19.87M | (92.27M) |
| EPS | 1.34 | 0.02 | 1.13 | 1.01 | 2.41 | 2.16 | 2.13 | 1.13 | 1.84 | 0.29 | 0.47 | -2.90 |
| Total Assets | 1.37B | 1.28B | 1.70B | 1.69B | 1.50B | 1.16B | 977.81M | 424.46M | 309.57M | 188.73M | 137.51M | 111.00M |
| Total Debt | 34.27M | 41.53M | 444.76M | 427.03M | 414.32M | 378.44M | 329.46M | 26.54M | 4.17M | 7.19M | 26.95M | 34.39M |
| Cash & Equivalents | 69.33M | 75.05M | 93.12M | 203.43M | 288.64M | 181.38M | 192.25M | 100.30M | 90.12M | 62.19M | 74.34M | 82.19M |
| Operating Cash Flow | 171.95M | 111.08M | 116.83M | 127.13M | 138.40M | 143.13M | 128.99M | 114.64M | 66.81M | 32.12M | 7.73M | (57.95M) |
| Free Cash Flow | 171.23M | 110.53M | 116.41M | 125.08M | 134.95M | 140.39M | 128.14M | 112.61M | 65.21M | 30.02M | 7.14M | (60.30M) |
| FCF per Share | 3.11 | 2.03 | 2.17 | 2.36 | 2.56 | 2.68 | 2.46 | 2.22 | 1.32 | 0.63 | 0.17 | -1.90 |
| Book Value | 1.04B | 921.52M | 886.20M | 815.85M | 744.86M | 595.43M | 453.02M | 267.48M | 191.75M | 118.88M | 71.35M | 33.46M |
| Cash & ST Investments | 453.61M | 254.87M | 461.33M | 339.68M | 422.53M | 347.07M | 356.02M | 140.04M | 90.12M | 62.19M | 74.34M | 82.19M |
| ROC Equity | 0.07 | 0.00 | 0.07 | 0.07 | 0.17 | 0.19 | 0.25 | 0.21 | 0.48 | 0.12 | 0.28 | -2.76 |